Clinical trials: Neoadjuvant Immunotherapy
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Head and Neck Squamous Cell Carcinoma
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection.
- Trial name
- NCT06444009
- Testing
- Ivonescimab combined with TP, Cadonilimab combined with TP, Penpulimab combined with TP
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lei Liu
NSCLC
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
- Trial name
- NCT05798663
- Testing
- Atezolizumab, Tiragolumab
- Where
- 15 sites in United States
- Volunteers
- 178 people
- Sponsor
- Alliance Foundation Trials, LLC.
Advanced Gastric Cancer, Neoadjuvant Therapy
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate…
- Conditions
- Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis
- Trial name
- NCT06376773
- Testing
- combination chemotherapy with Apatinib or Camrelizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Fujian Medical University
Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung…
- Conditions
- Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
- Trial name
- DRAGON-NSCLC (NCT07528066)
- Testing
- Robotic-assisted surgery (RATS)
- Where
- 10 sites in China, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer, Immunotherapy
Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
- Trial name
- Dupi-Cemi (NCT06743581)
- Testing
- Cemiplimab, Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Gastric Cancer
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
This is a single-institution, prospective phase II trial designed to evaluate the efficacy of neoadjuvant chemotherapy and sequential immunotherapy in patients with locally advanced esophagogastric junction and gastric…
- Trial name
- NCT05540145
- Testing
- SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoadjuvant Immunotherapy, NSCLC
Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which…
- Conditions
- Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy
- Trial name
- NCT07231575
- Testing
- SBRT, Immunotherapy, antiangiogenesis therapy
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Radiotherapy
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma
This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Radiotherapy, Immunotherapy, Surgery
- Trial name
- iCSDeR (NCT05476965)
- Testing
- induction therapy; surgery; radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hubei Cancer Hospital
Rectal Adenocarcinoma, High-Risk Cancer
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC
To explore the efficacy and safety of adding a ketogenic diet and/or high-dose intravenous vitamin C to neoadjuvant short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with serplulimab in patients with locally…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRI-KEV (NCT07765667)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer, Metastatic
The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer
The purpose of this study is to determine whether intraperitoneal immunotherapy (with interleykin-2 - human cytokine reaction activator) with systemic chemotherapy will be more effective than systemic chemotherapy alone in…
- Trial name
- NCT02976142
- Testing
- neoadjuvant chemoimmunotherapy
- Volunteers
- 150 people
- Sponsor
- Moscow Clinical Scientific Center
IMMUNOTHERAPY, Neoadjuvant Therapy
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
This study aims to evaluate the efficacy and safety of neoadjuvant camrelizumab combined with chemotherapy in resectable stage IIIA and IIIB (T3-4N2) non-small cell lung cancer (NSCLC) patients.
- Conditions
- IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
- Trial name
- NCT06241807
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Rectal Cancers
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
- Trial name
- NCT07622771
- Testing
- Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Tumor Regression Grade
PPIO-009 Tumor Regression Grade and Tumor Location in Esophageal Cancer
At present, the evaluation of the effect of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal cancer is mainly based on postoperative pathology, among which, the pathological assessment of…
- Trial name
- NCT06453395
- Testing
- Patients were grouped according to tumor location
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-Metastatic Breast Carcinoma
Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy
Background: Triple negative breast cancer (TNBC) is characterized by an aggressive biological behaviour responsible for higher risk of recurrence and shorter median survival.
- Trial name
- PEMCLOCK (NCT06418139)
- Testing
- No intervention
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Squamous Cell Carcinoma of the Head and Neck, Oropharynx
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Background: Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy
- Trial name
- NCT06223568
- Testing
- Docetaxel, Cisplatin, PRGN-2009
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Gastric Cancer
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer
- Trial name
- TJHGC01 (NCT06597227)
- Testing
- Proximal radical gastrectomy, Total radical gastrectomy
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Guihua Wang
Toripalimab, Surufatinib
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable…
- Conditions
- Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, Chemoradiotherapy
- Trial name
- NCT07086469
- Testing
- Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Nonsmall Cell, Non-Small Cell Lung Cancer NSCLC
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant…
- Trial name
- NCT06667154
- Testing
- Low-dose nivolumab combined with platinum-based doublet chemotherapy
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Aline Fusco Fares, MD